BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'. Br J Cancer 2019;120:141-53. [PMID: 30580378 DOI: 10.1038/s41416-018-0332-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 2021:S0923-7534(21)04824-9. [PMID: 34843940 DOI: 10.1016/j.annonc.2021.11.009] [Reference Citation Analysis]
2 Wang Z, Zhang T, Wu W, Wu L, Li J, Huang B, Liang Y, Li Y, Li P, Li K, Wang W, Guo R, Wang Q. Detection and Localization of Solid Tumors Utilizing the Cancer-Type-Specific Mutational Signatures. Front Bioeng Biotechnol 2022;10:883791. [DOI: 10.3389/fbioe.2022.883791] [Reference Citation Analysis]
3 Pisapia P, Costa JL, Pepe F, Russo G, Gragnano G, Russo A, Iaccarino A, de Miguel-Perez D, Serrano MJ, Denninghoff V, Quagliata L, Rolfo C, Malapelle U. Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. Crit Rev Oncol Hematol 2021;161:103311. [PMID: 33781866 DOI: 10.1016/j.critrevonc.2021.103311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Conway AM, Morris GC, Smith S, Vekeria M, Manoharan P, Mitchell C, Backen A, Oliveira P, Hubner RA, Lamarca A, McNamara MG, Valle JW, Cook N. Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. Br J Cancer 2022. [PMID: 35484217 DOI: 10.1038/s41416-022-01824-4] [Reference Citation Analysis]
5 Kolling S, Ventre F, Geuna E, Milan M, Pisacane A, Boccaccio C, Sapino A, Montemurro F. "Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"? Front Oncol 2019;9:1546. [PMID: 32010631 DOI: 10.3389/fonc.2019.01546] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
6 Chen S, Zhou W, Tu J, Li J, Wang B, Mo X, Tian G, Lv K, Huang Z. A Novel XGBoost Method to Infer the Primary Lesion of 20 Solid Tumor Types From Gene Expression Data. Front Genet 2021;12:632761. [PMID: 33613644 DOI: 10.3389/fgene.2021.632761] [Reference Citation Analysis]
7 Tran PH, Xiang D, Nguyen TN, Tran TT, Chen Q, Yin W, Zhang Y, Kong L, Duan A, Chen K, Sun M, Li Y, Hou Y, Zhu Y, Ma Y, Jiang G, Duan W. Aptamer-guided extracellular vesicle theranostics in oncology. Theranostics 2020;10:3849-66. [PMID: 32226524 DOI: 10.7150/thno.39706] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
8 Thambi T, Hong J, Yoon AR, Yun CO. Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses. Cancer Gene Ther 2022. [PMID: 35444290 DOI: 10.1038/s41417-022-00469-y] [Reference Citation Analysis]
9 Pouyiourou M, Wohlfromm T, Kraft B, Hielscher T, Stichel D, von Deimling A, Delorme S, Endris V, Neumann O, Stenzinger A, Krämer A, Bochtler T. Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. Eur J Cancer 2021;157:179-89. [PMID: 34521064 DOI: 10.1016/j.ejca.2021.08.019] [Reference Citation Analysis]
10 Ye Q, Wang Q, Qi P, Chen J, Sun Y, Jin S, Ren W, Chen C, Liu M, Xu M, Ji G, Yang J, Nie L, Xu Q, Huang D, Du X, Zhou X. Development and Clinical Validation of a 90-Gene Expression Assay for Identifying Tumor Tissue Origin. J Mol Diagn 2020;22:1139-50. [PMID: 32610162 DOI: 10.1016/j.jmoldx.2020.06.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Civantos FJ, Vermorken JB, Shah JP, Rinaldo A, Suárez C, Kowalski LP, Rodrigo JP, Olsen K, Strojan P, Mäkitie AA, Takes RP, de Bree R, Corry J, Paleri V, Shaha AR, Hartl DM, Mendenhall W, Piazza C, Hinni M, Robbins KT, Tong NW, Sanabria A, Coca-Pelaz A, Langendijk JA, Hernandez-Prera J, Ferlito A. Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era. Front Oncol 2020;10:593164. [PMID: 33244460 DOI: 10.3389/fonc.2020.593164] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Chakraborty S, Begg CB, Shen R. Using the "Hidden" genome to improve classification of cancer types. Biometrics 2021;77:1445-55. [PMID: 32914442 DOI: 10.1111/biom.13367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Tischoff I, Tannapfel A. [CUP in the liver]. Pathologe 2020;41:495-504. [PMID: 32588138 DOI: 10.1007/s00292-020-00803-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Argentiero A, Solimando AG, Brunetti O, Calabrese A, Pantano F, Iuliani M, Santini D, Silvestris N, Vacca A. Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. Cancers (Basel) 2019;11:E1270. [PMID: 31470608 DOI: 10.3390/cancers11091270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
15 Olivier T, Fernandez E, Labidi-Galy I, Dietrich PY, Rodriguez-Bravo V, Baciarello G, Fizazi K, Patrikidou A. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? Cancer Treat Rev 2021;97:102204. [PMID: 33866225 DOI: 10.1016/j.ctrv.2021.102204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ishiwata Y, Kaneta T, Nawata S, Iizuka H, Utsunomiya D. Feasibility of prognosis assessment for cancer of unknown primary origin using texture analysis of 18F-fluorodeoxyglucose PET/computed tomography images of largest metastatic lymph node. Nucl Med Commun 2021;42:86-92. [PMID: 33044405 DOI: 10.1097/MNM.0000000000001310] [Reference Citation Analysis]
17 Pisapia P, Pepe F, Iaccarino A, Sgariglia R, Nacchio M, Russo G, Gragnano G, Mosaieby E, Troncone G, Malapelle U. Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. JMP 2021;2:241-54. [DOI: 10.3390/jmp2030021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang Y, Xia L, Ma D, Wu J, Xu X, Xu Y. 90-Gene Expression Profiling for Tissue Origin Diagnosis of Cancer of Unknown Primary. Front Oncol 2021;11:722808. [PMID: 34692498 DOI: 10.3389/fonc.2021.722808] [Reference Citation Analysis]
19 Conway AM, Mitchell C, Cook N. Challenge of the Unknown: How Can We Improve Clinical Outcomes in Cancer of Unknown Primary? J Clin Oncol 2019;37:2089-90. [PMID: 31211603 DOI: 10.1200/JCO.19.00449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
20 Folprecht G, Trautmann K, Stein A, Huebner G, Stahl M, Kasper S, Kretzschmar A, Köhne CH, Grünwald V, Hofheinz RD, Schütte K, Löffler H, Bokemeyer C, Krämer A; Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP Group. Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. Br J Cancer 2021;124:721-7. [PMID: 33235314 DOI: 10.1038/s41416-020-01141-8] [Reference Citation Analysis]
21 Li X, Shao Y, Sheng L, Zhu J, Wang Z, Guo K, Sun L. Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site. Cancer Med 2021;10:974-88. [PMID: 33405390 DOI: 10.1002/cam4.3684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liu H, Qiu C, Wang B, Bing P, Tian G, Zhang X, Ma J, He B, Yang J. Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin. Front Cell Dev Biol 2021;9:619330. [PMID: 34012960 DOI: 10.3389/fcell.2021.619330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Al-Harake A, Dandache I, Moukadem H, Saliba M, Chahine J, Yazbeck H, Abdel-Sater F, Karnib H, Younes MH. Malignant carcinoma and skin melanoma neoplasms concomitantly in the thyroid. Clin Case Rep 2021;9:e04790. [PMID: 34552737 DOI: 10.1002/ccr3.4790] [Reference Citation Analysis]
24 L A, A E, A M, E M, M M. Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report. Current Problems in Cancer: Case Reports 2021;4:100097. [DOI: 10.1016/j.cpccr.2021.100097] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Laprovitera N, Riefolo M, Ambrosini E, Klec C, Pichler M, Ferracin M. Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers (Basel) 2021;13:451. [PMID: 33504059 DOI: 10.3390/cancers13030451] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Dermawan JK, Rubin BP. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary: Molecular profiling of metastatic cancer of unknown primary. Semin Diagn Pathol 2020:S0740-2570(20)30100-3. [PMID: 33309276 DOI: 10.1053/j.semdp.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Bochtler T, Krämer A. Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity? Front Oncol 2019;9:402. [PMID: 31165045 DOI: 10.3389/fonc.2019.00402] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
28 Creak A. Prospective Cohort of Referrals to a Cancer of Unknown Primary Clinic, including Direct Access from Primary Care. Clin Oncol (R Coll Radiol) 2020;32:e87-92. [PMID: 31635979 DOI: 10.1016/j.clon.2019.09.059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol 2020;17:541-54. [PMID: 32350398 DOI: 10.1038/s41571-020-0359-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
30 Koval AP, Blagodatskikh KA, Kushlinskii NE, Shcherbo DS. The Detection of Cancer Epigenetic Traces in Cell-Free DNA. Front Oncol 2021;11:662094. [PMID: 33996585 DOI: 10.3389/fonc.2021.662094] [Reference Citation Analysis]
31 Rassy E, Pavlidis N. The diagnostic challenges of patients with carcinoma of unknown primary. Expert Rev Anticancer Ther 2020;20:775-83. [PMID: 32779501 DOI: 10.1080/14737140.2020.1807948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Laprovitera N, Riefolo M, Porcellini E, Durante G, Garajova I, Vasuri F, Aigelsreiter A, Dandachi N, Benvenuto G, Agostinis F, Sabbioni S, Berindan Neagoe I, Romualdi C, Ardizzoni A, Trerè D, Pichler M, D'Errico A, Ferracin M. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Mol Oncol 2021. [PMID: 34075699 DOI: 10.1002/1878-0261.13026] [Reference Citation Analysis]
33 Candido PBM, Pinheiro RP, Peria FM, Toledo VN, Costa HRT, Defino HLA. UNKNOWN PRIMARY TUMOR SITES IN SPINAL METASTASIS. Coluna/Columna 2021;20:64-7. [DOI: 10.1590/s1808-185120212001243891] [Reference Citation Analysis]
34 Ding Y, Jiang J, Xu J, Chen Y, Zheng Y, Jiang W, Mao C, Jiang H, Bao X, Shen Y, Li X, Teng L, Xu N. Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. ESMO Open 2022;7:100407. [DOI: 10.1016/j.esmoop.2022.100407] [Reference Citation Analysis]
35 Stares M, Patton R, Knowles G, Haigh R, Barrie C, Dobbs L, McMillan D, Laird B, Clive S. A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin. Eur J Cancer 2020;139:1-9. [PMID: 32947141 DOI: 10.1016/j.ejca.2020.07.036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Blecua P, Davalos V, de Villasante I, Merkel A, Musulen E, Coll-SanMartin L, Esteller M. Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary. Brief Bioinform 2022:bbac161. [PMID: 35524475 DOI: 10.1093/bib/bbac161] [Reference Citation Analysis]
37 Shao Y, Liu X, Hu S, Zhang Y, Li W, Zhou X, Wang Q, Hou Y, Chen Y, Wang Y, Wang Y, Luo Z, Hu X. Sentinel node theory helps tracking of primary lesions of cancers of unknown primary. BMC Cancer 2020;20:639. [PMID: 32646508 DOI: 10.1186/s12885-020-07042-6] [Reference Citation Analysis]